Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was noted to have acute tubulointerstitial nephritis on renal biopsy. Pembrolizumab was discontinued and the patient was started on long-term corticosteroids with a taper. Her renal function improved partially with treatment.
Medicina (Kaunas, Lithuania)
Basnet, S., Dhital, R., & Tharu, B. (2019). Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.. Medicina (Kaunas, Lithuania), 55 (5), E176-E176. https://doi.org/10.3390/medicina55050176.